This collaborative approach, alongside the FDA approval of innovative products like EMBLAVEO, has reinforced investor confidence. Despite facing challenges such as fluctuating profit margins and ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections. The drug – a combination of beta-lactam antibiotic aztreonam with beta ...

The CHMP also backed approval of Pfizer’s antibiotic infusion Emblaveo (aztreonam-avibactam) to treat complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI ...

AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and ...

PwC has released its latest Global Top 100 report ranking the largest public companies by market cap as of the end of March 2024.

Pediatr Infect Dis J. 2015;34(8):849-850. Piperacillin–tazobactam is a safe antimicrobial agent frequently used in pediatric patients for the treatment of complicated appendicitis, cystic ...

Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) Meningococcal vaccine For active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in ...

The following table presents notable drug approvals of February 2025. Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) Meningococcal vaccine For active immunization to prevent invasive ...